{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:11:48Z","timestamp":1790748708687,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T07:21:22Z","timestamp":1651562482000},"page":"S88-S96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Interactions m\u00e9dicamenteuses et incompatibilit\u00e9s physico-chimiques en phase aigu\u00eb post-allogreffe\u00a0: quelle influence des m\u00e9dicaments de support\u00a0? Recommandations de la SFGM-TC"],"prefix":"10.1016","volume":"110","author":[{"given":"B\u00e9n\u00e9dicte","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Capelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorea","family":"Selmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Villate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Cabelguenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Lachner-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.02.004_bib0170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-019-03791-9","article-title":"Potential drug\u2013drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay","volume":"83","author":"Sanchez","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0175","article-title":"Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults","volume":"27","author":"Sugidono","year":"2021","journal-title":"Trans Cell Ther"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0180","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00280-014-2657-8","article-title":"Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation","volume":"75","author":"Trevisan","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.02.004_bib0185","first-page":"47","article-title":"Comparison of the efficacy of posaconazole delayed release tablets and suspension in pediatric hematology\/oncology patients","volume":"25","author":"Wass","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835918818347","article-title":"Clinically relevant drug interactions with multikinase inhibitors: a review","volume":"11","author":"Hussaarts","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0195","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-016-2782-z","article-title":"Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients","volume":"95","author":"Yasu","year":"2016","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.02.004_bib0200","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.04838-14","article-title":"Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels","volume":"59","author":"Gautier-Veyret","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.bulcan.2022.02.004_bib0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1574886311207040262","article-title":"Drug-induced QTc interval prolongation: a multicenter study to detect drugs and clinical factors involved in every day practice","volume":"11","author":"Keller","year":"2016","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-018-2602-6","article-title":"Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and haematology units","volume":"75","author":"Maison","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.bulcan.2022.02.004_bib0215","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2146\/ajhp070572","article-title":"Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients","volume":"66","author":"Canann","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/jrpp.JRPP_20_11","article-title":"Intravenous drug incompatibilities in the intensive care unit of tertiary care hospital in India: are they preventable?","volume":"92","author":"Sriram","year":"2020","journal-title":"J Res Pharm Pract"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ejhpharm-2017-001248","article-title":"Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine pediatric care","volume":"26","author":"Neininger","year":"2019","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.bulcan.2022.02.004_bib0230","first-page":"23","article-title":"Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia","volume":"68","author":"Le Clech","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"6","key":"10.1016\/j.bulcan.2022.02.004_bib0235","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00134-012-2539-7","article-title":"In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial","volume":"38","author":"Jack","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2431-13-21","article-title":"In-line filtration minimizes organ dysfunction: new aspects from a prospective, randomized, controlled trial","volume":"13","author":"Boehne","year":"2013","journal-title":"BMC Pediatr"},{"issue":"2","key":"10.1016\/j.bulcan.2022.02.004_bib0245","first-page":"173","article-title":"Clinical implications of intravenous drug incompatibilities in critically ill patients","volume":"38","author":"Benlabed","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0250","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0255","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et autres produits de sant\u00e9. Th\u00e9saurus des interactions m\u00e9dicamenteuses. https:\/\/ansm.sante.fr\/documents\/reference\/thesaurus-des-interactions-medicamenteuses-1."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0260","unstructured":"Theriaque. http:\/\/www.theriaque.org\/ [consult\u00e9 le 17\/09\/2021]."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0265","unstructured":"GPR-Diane. http:\/\/sitegpr.com\/fr\/ [consult\u00e9 le 17\/09\/2021]."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0270","unstructured":"Stabilis\u00a0\u2013\u00a0Stabilit\u00e9 et compatibilit\u00e9 des m\u00e9dicaments. https:\/\/www.stabilis.org\/ [consult\u00e9 le 17\/09\/2021]."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0275","unstructured":"King guide to parenteral admixtures. https:\/\/www.libraries.rutgers.edu\/databases\/kgpa [consult\u00e9 le 17\/09\/2021]."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0280","unstructured":"Pharmacie des H\u00f4pitaux Universitaires de Gen\u00e8ve. Compatibilit\u00e9 des m\u00e9dicaments administr\u00e9s en Y. https:\/\/pharmacie.hug.ch\/infomedic\/utilismedic\/HUG_CompatAdm_DCI.pdf [consult\u00e9 le 17\/09\/2021]."},{"issue":"1S","key":"10.1016\/j.bulcan.2022.02.004_bib0285","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.bulcan.2018.07.020","article-title":"[Clinical pharmacy in a bone marrow and cellular therapy transplantation ward-which methods to put in place: guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"106","author":"Forcade","year":"2019","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2022.02.004_bib0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/metabo11030173","article-title":"Does DDI-Predictor help pharmacists to detect drug-drug interactions and resolve medication issues more effectively?","volume":"11","author":"Moreau","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0295","unstructured":"DrugBank Online. Database for Drug and Drug Target Info. https:\/\/go.drugbank.com\/ [consult\u00e9 le 17\/09\/2021]."},{"key":"10.1016\/j.bulcan.2022.02.004_bib0300","first-page":"348","article-title":"Mise en place d\u2019un outil d\u2019aide \u00e0 la d\u00e9tection des interactions physico-chimiques en Y des m\u00e9dicaments injectables\u00a0: analyse r\u00e9trospective des prescriptions dans un service d\u2019h\u00e9matologie","volume":"54","author":"Sicard","year":"2019","journal-title":"Pharm Hosp Clin"},{"issue":"1","key":"10.1016\/j.bulcan.2022.02.004_bib0305","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12911-020-01231-w","article-title":"Towards more efficient use of intravenous lumens in multi-infusion settings: development and evaluation of a multiplex infusion scheduling algorithm","volume":"20","author":"Doesburg","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0310","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40635-018-0205-2","article-title":"Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof-of-concept in vitro study","volume":"6","author":"Benlabed","year":"2018","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0315","series-title":"Outils de s\u00e9curisation et d\u2019auto-\u00e9valuation de l\u2019administration des m\u00e9dicaments","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2013"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0320","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11096-010-9422-9","article-title":"A purging procedure for pantoprazole and 4-lumen catheters to prevet IV drug incompatibilities","volume":"32","author":"Bertsche","year":"2010","journal-title":"Pharm World Sci"},{"issue":"6","key":"10.1016\/j.bulcan.2022.02.004_bib0325","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/pbc.25442","article-title":"In vitro analysis of overall particulate contamination exposure during multidrug IV therapy: impact of infusion sets","volume":"62","author":"Perez","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.02.004_bib0165","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie clinique\u00a0\u2013\u00a0Groupe de travail Optimisation des pratiques de pr\u00e9paration et de perfusion. https:\/\/sfpc.eu\/o3p\/ [consult\u00e9 le 17\/09\/2021]."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:19Z","timestamp":1757792239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122000789"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.02.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions m\u00e9dicamenteuses et incompatibilit\u00e9s physico-chimiques en phase aigu\u00eb post-allogreffe\u00a0: quelle influence des m\u00e9dicaments de support\u00a0? Recommandations de la SFGM-TC","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}